CN1602872A - Antituberculosis pharmaceutical composition - Google Patents
Antituberculosis pharmaceutical composition Download PDFInfo
- Publication number
- CN1602872A CN1602872A CN 03151413 CN03151413A CN1602872A CN 1602872 A CN1602872 A CN 1602872A CN 03151413 CN03151413 CN 03151413 CN 03151413 A CN03151413 A CN 03151413A CN 1602872 A CN1602872 A CN 1602872A
- Authority
- CN
- China
- Prior art keywords
- drug
- pyrazinamide
- agent compositions
- tablet
- antitubercular agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to an antituberculosis drug combination, prepared of rifampicin, isonicotinyl hydrazine, pyrazinamide, ethambutol hydrochloride and other auxiliaries, able to effectively overcome problems of drug resistance, improving compliance of patient, etc. It is applied in a compound form, which can avoid curing by single antituberculosis drug, thus avoiding selective drug resistance caused by single drug; the patients are willing to accept this, avoiding irregular drug application caused by simultaneously taking several drugs and different numbers of drug tablets, or taking more or less drugs.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition, relate in particular to a kind of antitubercular agent compositions.
Background technology
Tuberculosis is a kind of chronic infectious disease, and it has been played vaccine and also can't guarantee to get anything but tuberculosis unlike variola or poliomyelitis.The data introduction is arranged, and in recent years, because people loosen tuberculosis vigilance, poverty and recurrent population roll up, and the appearance of Resistant strain, acquired immune deficiency syndrome (AIDS), and big rise has all appearred in tuberculosis all over the world.World Health Organization's report, tuberculosis remain the first killer of infectious disease, and the whole world has the people of 1/3 (about 2,000,000,000) to infect tulase approximately, and in existing 2,000 ten thousand tuberculosis patients, 95% in developing country.About 9,000,000 patients of the new appearance in the annual whole world, wherein 75% patient age was at 15～50 years old.As not controlling, also will there be 9,000 ten thousand people to fall ill in 10 years from now on.Serious day by day multiple drug resistance case increases, and will threaten tuberculosis to get back to the age of " incurable disease " again.As not taking strong measure immediately, the even more serious popular and threat of tuberculosis will be caused.China remains one of 22 the heaviest countries of the burden of tuberculosis in the world, the whole nation infected number about 400,000,000, the number of hectic reaches more than 600 ten thousand, wherein the infectiousness consumptive more than 200 ten thousand, annual because of the dead number of tuberculosis reaches 250,000 people, be 2 times of all kinds of infectious disease death toll summations.Tuberculosis Epidemiological study result shows, except that teenager tuberculosis morbidity height, the old people in 60-70 year also is onset peak.Its reason one is old people's immunologic function degression, and the old people merges the resume combustion that pulmonary and systemic disease can cause conceal type or old focus in addition.The 2nd, present old people, in adolescence tuberculosis the most rampant popular age on China's history just, the overwhelming majority was subjected to the infection of tuberculosis, but not morbidity.When entering old age, body's immunity descends, and makes the tuberculosis recurrence; Fall ill when also some old tuberculosis is teenager, be subjected at that time that historical conditions limits, do not obtain regular treatment timely, to old recurrence.The 3rd, aged tendency of population, the aging population ratio increases, and old tuberculosis constituent ratio is increased.
Be used for the single medicine that mostly is lungy at present, antiphthisic treatment time is long, and not only the pulmonary tuberculosis bacterium can not kill, and also can produce Resistant strain; And during conventional therapy, patient must take corrected and antitubercular agent capacity, causes that easily the light patient of body weight causes side effect because of high dose, and the high patient of body weight is difficult for obtaining ideal treatment.In addition, because the medication amount of taking simultaneously is more, patient's compliance is bad, easily causes wrong clothes, misses etc. to be unfavorable for the behavior for the treatment of.Medicine can be avoided single antitubercular agent treatment with the form administration of compound recipe, thus the selectivity drug resistance of avoiding single medicine to cause; Patient takes like a shot, and has avoided obeying multiple medications simultaneously and each tablet quantity does not wait the irregular medication that is caused, or the many clothes and the thing of taking medicine less; Simplify the storage management of medicine; Simplify therapeutic scheme, the direct face of being more convenient for is looked down short-course chemotherapy (DOTS) management of administration.
Therefore, develop a kind of novel antituberculosis drug to current treatment pulmonary tuberculosis with to overcome chemical sproof meaning very great.
Summary of the invention
The object of the present invention is to provide a kind ofly can effectively overcome drug resistance, improve patient's compliance, improve the antitubercular agent compositions of therapeutic effect.
A kind of antitubercular agent compositions of the present invention is the medicament of being made by Rimactazid, pyrazinamide, ebutol and other pharmaceutical adjunct; Pharmaceutical adjunct is a microcrystalline Cellulose, pregelatinized Starch, magnesium stearate, dextrin, lactose, micropowder silica gel, one or more mixing in the amylum pregelatinisatum; Said medicament is tablet or capsule; In tablet, contain rifampicin 50g～150g, isoniazid 30g～60g, pyrazinamide 100g～300g, ebutol 65g～150g in per 1000; Optimum content is to contain rifampicin 75g, isoniazid 37.5g, pyrazinamide 200g, ebutol 137.5g, microcrystalline Cellulose 50g, pregelatinized Starch 75g, magnesium stearate 1.5g in the tablet in per 1000; The present invention also provides the preparation method of this antituberculotics tablet, takes by weighing rifampicin, ebutol, isoniazid, pyrazinamide, microcrystalline Cellulose and pregelatinized Starch, magnesium stearate by prescription, and mixing is with 12mm punch die tabletting, promptly.
Antituberculotics of the present invention can be avoided single antitubercular agent treatment with the form administration of compound recipe, thus the selectivity drug resistance of avoiding single medicine to cause; Patient takes like a shot, and has avoided obeying multiple medications simultaneously and each tablet quantity does not wait the irregular medication that is caused, or the many clothes and the thing of taking medicine less.
The specific embodiment
Embodiment: the preparation of the tablet of the present composition
Prescription:
Rifampicin 75.0g
Ebutol 137.5g
Isoniazid 37.5g
Pyrazinamide 200.0g
Microcrystalline Cellulose 50g
Pregelatinized Starch 70g
Magnesium stearate 1.5g
Make 1000
Take by weighing rifampicin, ebutol, isoniazid, pyrazinamide, microcrystalline Cellulose and pregelatinized Starch, magnesium stearate by prescription, mixing with 12mm punch die tabletting, makes tablet, can also wrap film-coat, obtains Film coated tablets.
Claims (6)
1, a kind of antitubercular agent compositions is characterized in that the medicament of being made by Rimactazid, pyrazinamide, ebutol and other pharmaceutical adjunct.
2, a kind of antitubercular agent compositions according to claim 1 is characterized in that other pharmaceutical adjunct is a microcrystalline Cellulose, pregelatinized Starch, magnesium stearate, dextrin, lactose, micropowder silica gel, one or more mixing in the amylum pregelatinisatum.
3, a kind of antitubercular agent compositions according to claim 1 is characterized in that said medicament is tablet or capsule.
4, a kind of antitubercular agent compositions according to claim 3 is characterized in that containing in per 1000 in the tablet rifampicin 50g～150g, isoniazid 30g～60g, pyrazinamide 100g～300g, ebutol 65g～150g.
5,, it is characterized in that containing rifampicin 75g, isoniazid 37.5g, pyrazinamide 200g, ebutol 137.5g, microcrystalline Cellulose 50g, pregelatinized Starch 75g, magnesium stearate 1.5g in per 1000 of the tablet according to claim 3 or 4 described a kind of antitubercular agent compositions.
6, according to the preparation method of the tablet of claim 3,4 or 5 described a kind of antitubercular agent compositions, it is characterized in that taking by weighing rifampicin, ebutol, isoniazid, pyrazinamide, microcrystalline Cellulose and pregelatinized Starch, magnesium stearate by prescription, mixing, with 12mm punch die tabletting, promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03151413 CN1602872A (en) | 2003-09-29 | 2003-09-29 | Antituberculosis pharmaceutical composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03151413 CN1602872A (en) | 2003-09-29 | 2003-09-29 | Antituberculosis pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1602872A true CN1602872A (en) | 2005-04-06 |
Family
ID=34659926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03151413 Pending CN1602872A (en) | 2003-09-29 | 2003-09-29 | Antituberculosis pharmaceutical composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1602872A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010009572A1 (en) * | 2008-07-23 | 2010-01-28 | 国防教育研究基金会 | New low side effect pharmaceutical composition containing isoniazid |
| CN102106855A (en) * | 2009-12-24 | 2011-06-29 | 杭州赛利药物研究所有限公司 | Pharmaceutical preparation for resisting tuberculosis and preparation method thereof |
| WO2012139485A1 (en) * | 2011-04-12 | 2012-10-18 | 浙江海正药业股份有限公司 | Oral solid preparation of compound antituberculosis drug and preparation method thereof |
| CN104274456A (en) * | 2013-07-02 | 2015-01-14 | 安徽贝克生物制药有限公司 | Quadrigeminal compound preparation of anti-tuberculosis medicines and preparation method thereof |
| CN104418864A (en) * | 2013-08-30 | 2015-03-18 | 西南大学 | Conjugates of dihydroartemisinin and quinolones compounds as well as preparation method and application thereof |
| CN108186638A (en) * | 2018-03-08 | 2018-06-22 | 重庆华邦制药有限公司 | The pharmaceutical composition of isoniazid |
-
2003
- 2003-09-29 CN CN 03151413 patent/CN1602872A/en active Pending
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010009572A1 (en) * | 2008-07-23 | 2010-01-28 | 国防教育研究基金会 | New low side effect pharmaceutical composition containing isoniazid |
| CN102137671A (en) * | 2008-07-23 | 2011-07-27 | 国防教育研究基金会 | New low side effect pharmaceutical composition containing isoniazid |
| CN102137671B (en) * | 2008-07-23 | 2012-10-17 | 国防教育研究基金会 | New low side effect pharmaceutical composition containing isoniazid |
| CN102106855A (en) * | 2009-12-24 | 2011-06-29 | 杭州赛利药物研究所有限公司 | Pharmaceutical preparation for resisting tuberculosis and preparation method thereof |
| CN102106855B (en) * | 2009-12-24 | 2014-04-09 | 杭州赛利药物研究所有限公司 | Pharmaceutical preparation for resisting tuberculosis and preparation method thereof |
| WO2012139485A1 (en) * | 2011-04-12 | 2012-10-18 | 浙江海正药业股份有限公司 | Oral solid preparation of compound antituberculosis drug and preparation method thereof |
| RU2605388C2 (en) * | 2011-04-12 | 2016-12-20 | Чжэцзян Хисун Фармасьютикал Ко., Лтд. | Oral solid preparation of compound antituberculosis drug and preparation method thereof |
| US9555003B2 (en) | 2011-04-12 | 2017-01-31 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Oral solid formulation of compound anti-tubercular drug and preparation method thereof |
| CN104274456A (en) * | 2013-07-02 | 2015-01-14 | 安徽贝克生物制药有限公司 | Quadrigeminal compound preparation of anti-tuberculosis medicines and preparation method thereof |
| CN104418864A (en) * | 2013-08-30 | 2015-03-18 | 西南大学 | Conjugates of dihydroartemisinin and quinolones compounds as well as preparation method and application thereof |
| CN104418864B (en) * | 2013-08-30 | 2016-06-08 | 西南大学 | Conjugate of dihydroarteannuin and carbostyril compound and its preparation method and application |
| CN108186638A (en) * | 2018-03-08 | 2018-06-22 | 重庆华邦制药有限公司 | The pharmaceutical composition of isoniazid |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9072697B2 (en) | Composition and method for treating neurological disease | |
| US5594030A (en) | Controlled release pharmaceutical compositions based on one or more pharmaceutically acceptable salts of gamma hydroxy-butyric acid | |
| US5599577A (en) | Simethicone containing pharmaceutical compositions | |
| US10166207B2 (en) | Acamprosate formulations, methods of using the same, and combinations comprising the same | |
| US20090253728A1 (en) | Methods and Compositions for Treating Nociceptive Pain | |
| JPH02503682A (en) | treatment of obesity | |
| KR970064599A (en) | Sustained release formulations | |
| CA2563058A1 (en) | Supportive treatment of liver disease | |
| EP0451484A1 (en) | Deprenyl/L-dopa/carbidopa pharmaceutical composition | |
| IL159591A (en) | Terbinafine solid dosage forms for oral administration and uses thereof in the preparation of medicaments | |
| CN102008708B (en) | Ramipril-contained compound preparation for treating hypertension | |
| CN1602872A (en) | Antituberculosis pharmaceutical composition | |
| JPH04295424A (en) | Acetyl-l-carnitin and medicinal composition for treating coma | |
| EP2830605B1 (en) | A combination medicament comprising phenylephrine and paracetamol | |
| US6559180B2 (en) | Nitroglycerin-menthol potentiation for treatment of angina | |
| KR101816726B1 (en) | Controlled-release tablet containing bepotastine | |
| US20080311196A1 (en) | All Day Rhinitic Condition Treatment Regimen | |
| US3150043A (en) | Anorectic composition | |
| JP4318899B2 (en) | Anti-cold medicine | |
| Ulm | Effect of budipine on parkinsonian tremor resistant to other antiparkinsonian medication | |
| Muenter | Pharmacotherapy: Problems and Practices | |
| ZA200400192B (en) | Pharmaceutical compositions containing terbinafin and use thereof. | |
| CN1788727A (en) | Compound dispersion tablet containing brufen for treating cold |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |